Skip to main content
PMC home page
Journal of Cardiovascular and Thoracic Research logoLink to Journal of Cardiovascular and Thoracic Research
. 2018 Sep 25;10(3):118–128. doi: 10.15171/jcvtr.2018.20

A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn.

Fataneh Hashem-Dabaghian 1,2, Mojtaba Ziaee 3, Samad Ghaffari 3, Farzaneh Nabati 4, Saeed Kianbakht 4,*
PMCID: PMC6203864  PMID: 30386531

Abstract

Introduction: The Emblica officinalis (EO) fruit has traditionally been considered as a cardioactive medication and has demonstrated remarkable cardiovascular effects in the pharmacological literature. The present study systematically reviews EO’s potential for prevention and therapy of cardiovascular diseases (CVD).

Methods: PubMed, ScienceDirect, Scopus, Proquest, Ebsco, Google, Google Scholar, Ovid, and Cochrane databases were searched from 1966 to 2017 for the English and non-English literature using the terms including the cognates of EO including amla, Emblic myrobalan, Emblica officinalis, Emblica pectinata , Indian gooseberry, and Phyllanthus emblica together with antioxidant, arrhythmia, cardioprotective, cardiotoxicity, heart disease, heart failure, hyperlipidemia, hypertension, myocardial dysfunction, and oxidative stress. The inclusion criteria were in vitro, animal, and clinical cardiovascular pharmacological studies conducted on EO and full-text accessibility. The exclusion criterion was studies in which a combination of EO and at least one other plant was investigated. The reference lists of the retrieved articles were also searched manually for additional eligible articles. The methodological quality of clinical trials was assessed by the Jadad scale, and animal studies were evaluated by the ARRIVE checklist.

Results: Nineteen articles concerning the cardiovascular pharmacological effects of EO were included in this review. The plant has shown antiatherogenic, anticoagulant, hypolipidemic, antihypertensive, antioxidant, antiplatelet, and vasodilatory effects as well as lipid deposition inhibitory properties. Moreover, it prevents from doxorubicin and isoproterenol cardiotoxicity and myocardial ischemia/reperfusion injury, and improves vascular endothelial function in animal studies. Some high-quality clinical studies report the vasodilatory and myocardial antioxidant properties as well as anti-platelet aggregation effects of this plant.

Conclusion: EO influences various cardiovascular risk-factors. However, there is not sufficient evidence to confirm the plant efficacy in preventing and treating CVD.

Keywords: Emblica officinalis, Cardiovascular Disease, Pharmacology, Phyllanthus emblica, Amla

Introduction

Cardiovascular diseases (CVD) are the leading cause of death worldwide, resulting in 17.9 million deaths in 20151 and expectedly exceeding 23.6 million by 2030.2

Some medicinal plants and food components (as monotherapy or adjunct to standard pharmacotherapy) have traditionally been used to treat CVD and have demonstrated various cardiovascular pharmacological effects.3-6 Emblica officinalis is one of the medicinal plants whose cardiovascular effects have been considered both in the traditional medicine and in the modern scientific literature.

Emblica officinalis Gaertn. (Other names: Phyllanthus emblica Linn. and Emblica pectinata Ridl.) (family Euphorbiaceae), also known as Emblic myrobalan, Indian gooseberry, or amla, hereafter referred to as EO. This medium-sized deciduous tree is native to India and cultivated in Pakistan, Uzbekistan, Sri Lanka, South East Asia, China, and Malaysia.7 The EO fruits are used more than the other parts of the plant for treatment of various diseases in the Ayurveda and Unani medicines.7 The dried fruit is a common imported herbal product in the herbal markets of Iran. The fresh fruits resemble green sour plums about the size of a walnut (Figure 1). The fruit contains tannins, alkaloids, phenols, amino acids, carbohydrates, vitamins, flavonoids, and organic acids (Table 1 and Figure 2).8,9 The fruit is highly nutritious and consumed as a food.10,11

Figure 1.

Figure 1

Picture of the Emblica officinalis fruits.

Open in a new tab

Table 1. Compounds of Emblica officinalis .

Class of compounds Compounds
Hydrolysable tannins Emblicanin A and B, punigluconin, pedunculagin, chebulinic acid (ellagitannin), chebulagic acid (benzopyran tannin), corilagin (ellagitannin), geraniin (dehydroellagitannin), ellagotannin
Alkaloids Phyllantine, phyllembein, phyllantidine
Phenols Gallic acids, methyl gallate, ellagic acid, trigallayl glucose
Amino acids Glutamic acid, proline, aspartic acid, alanine, cystine, lysine
Carbohydrates Pectin
Vitamins Ascorbic acid
Flavonoids Quercetin, kaempferol
Organic acids Citric acids
Open in a new tab

Figure 2.

Figure 2

Structural formula of some important compounds of Emblica officinalis.

Open in a new tab

The EO fruit has also been mentioned in the literature of the Persian medicine (PM).12 EO is one of the 50 cardio-active plants mentioned in the Avicenna book “The Treatise on Cardiac Drugs”.13 Cardiotonic action is one of the features attributed to this plant in the PM.12-14 From the PM perspective, the fruit can be cardiotonic because it has astringent properties and can strengthen the cardiac tissue.15 Besides, it can affect the heart by exerting impact on stomach diseases (including gastro-esophageal reflux and mal-temperaments of the stomach, which are, as noted, related to cardiac diseases).14 Pharmacological studies have demonstrated diverse cardiovascular and other impacts for the fruit such as cytotoxic, hypoglycemic, hypolipidemic, hepatoprotective, cardioprotective, antiatherogenic, antioxidant, antipyretic, analgesic, antimicrobial, diuretic, and laxative effects.7,16-18

Numerous studies have been published on the effects of EO on various CVD; however, there has been no systematic review regarding the cardiovascular effects of EO nor is there a definitive decision on the efficacy of this plant. Therefore, this review was conducted to evaluate the plant potential for prevention and treatment of CVD.

Materials and Methods

To collect the studies on the cardiovascular effects of EO, PubMed, Science Direct, Scopus, Proquest, Ebsco, Google, Google Scholar, Ovid, and Cochrane databases were searched for the English and non-English literature from 1966 to 2017 using the terms amla, Emblic myrobalan, Emblica officinalis, Emblica pectinata, Indian gooseberry, and Phyllanthus emblica together with antioxidant, arrhythmia, cardioprotective, cardiotoxicity, heart disease, heart failure, hyperlipidemia, hypertension, myocardial dysfunction, and oxidative stress. The database of Irandoc and the online libraries of Iranian universities were also searched for the purposes of this study.

Three persons performed the literature search and assessment. The inclusion criteria were in vitro, animal, and clinical cardiovascular pharmacological studies conducted on EO and full-text accessibility. The exclusion criterion was studies in which a combination of EO and at least one other plant was investigated. The reference lists of the retrieved articles were searched manually for additional eligible articles. All published cardiovascular pharmacological studies fulfilling the search criteria were included in the results section.

For clinical studies, PICO was considered as patients with a type of cardiovascular disease who took the EO with or without a control group with the aim to identify changes in CVD during intervention.

The methodological quality of clinical trials was assessed by the Jadad scale in terms of the presence of randomization, masking, and accountability of all patients including withdrawals, as described in the literature.19 The methodological quality of animal studies was assessed by ARRIVE checklist.20

The PRISMA flow diagram of this review is presented in Figure 3.

Figure 3.

Figure 3

The PRISMA flow diagram of the study.

Open in a new tab

Results

There were no non-English and gray literature, theses and dissertations conforming to the search criteria. Summaries of the cardiovascular pharmacological studies fulfilling the search criteria are presented in Tables 2 and 3.

Table 2. Summary of the experimental pharmacological studies regarding the cardiovascular effects of Emblica officinalis .

Author, year Methodological quality Study design/participants/
inclusion criteria 		Intervention/control group Outcome measure Results
Thakur CP. 198821 High N:100 (4 groups)
cholesterol-induced hypercholesterolemic albino rabbits 		Group1- control group (cholestrol 0.3 g/kg)
Group 2- Terminalia chebula group (Terminalia chebula+ cholesterol)
Group 3- Terminalia belerica group (Terminalia belerica + cholesterol)
Group 4- the amla group (1 g/kg powdered EO + cholesterol, all interventions PO daily for 16 weeks 		Serum TC, TG and LDL-C;
cholesterol contents of the liver and aorta; fecal excretion of cholesterol 		Decrease in serum TC and LDL-C, aortic and hepatic cholesterol, possibly through enzymatic degradation of cholesterol.
No effect on fecal excretion of cholesterol.
No effect on the serum TG.
Mathur R. 199622 Medium N: 28 (4 groups)
cholesterol-induced hypercholesterolemic rabbits 		Group 1-(control) vehicle treated for 60 and 120 days.
Group 2- cholesterol feeding (400 mg/kg per day) for 60 and 120 days
Group 3- cholesterol feeding for 60 days; afterward, cholesterol diet was withdrawn; control diet + fresh juice of EO from day 61 to day 120 (5 mL juice/kg per day).
Group 4- cholesterol feeding + EO juice from day 1 to day 120 (concurrent feeding). 		Serum TC, TG, LDL-C, VLDL-C and HDL-C; liver, ventricular muscle and aortic TC,TG and phospholipids contents. Decrease in TC, TG and LDL-C levels.
Decrease in the lipid levels of tissues.
Regression of aortic plaques.
Increase of fecal excretion of cholesterol and phospholipid.s.
Anila L. 200223 High N:30 (3 groups)
cholesterol-induced hypercholesterolemic albino rats. 		Group I - control
Group II- flavonoids
of EO10 mg/kg /day
Group III - flavonoids of Mangifera indica
PO for 90 days 		Serum and liver LDL-C and VLDL-C and serum HDL-C. HMG-CoA activity. Decrease of LDL-C and VLDL-C in serum and liver.
Unchanged serum HDL-C.
Inhibition of HMG-CoA and increased degradation and elimination of cholesterol.
Bhattacharya SK. 200224 High N:62 (8 groups)
rat model of cardiac IRI 		Group 1-saline perfusion (SP) for 30 minutes
Group 2- tannoid principles of EO (EOT) (50 mg/kg) + SP
Group 3-EOT (100 mg/kg) + SP
Group 4-vitamin E (200mg/kg) + SP
Group 5- IRI
Group 6-EOT (50 mg/kg) + IRI
Group 7-EOT (100 mg/kg) + IRI
Group 8-vitamin E (200mg/kg) + IRI
All perfused twice daily for 14 days 		Cardiac SOD, catalase, glutathione peroxidase activity and lipid peroxidation Both EOT (50 and 100 mg/kg) and vitamin E prevented IRI-induced effects (decrease in the activities of cardiac SOD, catalase and glutathione peroxidase, and increase in lipid peroxidation)
Rajak S. 200425 Medium N:64 rats (4 groups)
rat model of cardiac IRI 		Group1- normal rat
Group 2- EO juice 250 mg/kg/day PO for 30 days
Group 3- EO juice 500 mg/kg/day PO for 30 days
Group 4- EO juice 750 mg/kg/day PO for 30 days 		Myocardial TBARS (a measure of lipid peroxidation) content.
Myocardial reduced glutathione,
catalase, superoxide dismutase,
glutathione peroxidase. 		No significant increase in myocardial TBARS and depletion of antioxidant enzymes were observed after IRI in the treated groups.
Myocyte injury was evident only in 250 mg/kg group.
Anthony B. 200626 Medium N:24 (4 groups)
cholesterol-induced hypercholesterolemic rabbits. 		Group 1- normal control
Group 2- hypercholestrlemic control (vehicle PO)
Group 3- Ethanol extract of EO 10 mg/kg/day PO
Group 4- ethanol extract of EO 20 mg/kg/day
PO for 4 months 		Serum TC, TG, HDL-C, LDL-C; aortic atheromatous plaque; heart, liver and kidney cholesterol contents; HMG-CoA activity Decrease of serum total cholesterol, TG and LDL-C; HDL-C increase; reduction of aortic atheromatous plaques; decrease of heart, liver and kidney cholesterol contents.
Inhibition of HMG-CoA.
Patel SS. 201127 Medium N:48 rats (4 groups)
rat model of diabetic-induced myocardial dysfunction 		Group1- non-diabetic control Group 2-diabetic control
Group 3-non-diabetic treated with EO juice 1 mL/kg/day PO for 8 weeks
Group 4-diabetic treated with EO juice 1 mL/kg/day 		Body weight, lipid profile, heart rate, BP, serum LDH and creatinine kinase-MB EO prevented weight loss, hyperglycemia, dys-lipidemia, myocardial hypertrophy and cardiomyopathy; increased heart rate and force of contraction; Decreased BP and serum LDH and creatine kinase-MB in diabetic rats.
Bhatia J. 201128 High N:36 (6 groups)
rat model of DOCA-salt-induced hypertension 		Group 1- control group (vehicle)
Group 2- DOCA 20 mg/kg SC plus
1% NaCl solution PO
Groups 3–5- DOCA 20 mg/kg SC plus 1% NaCl solution and
E. officinalis 75, 150 and 300 mg/kg/day PO,
respectively
Group 6: neither received DOCA 20 mg/kg SC nor
1% NaCl solution, received only E. officinalis 300 mg/kg/day PO plus normal drinking water. 		SBP, DBP, mean arterial pressure, heart rate. Oxidative stress in serum, heart and kidney. Heart and kidney weights/100 g body weight ratio Decrease of SBP, DBP, mean arterial pressure and heart rate.
Increase of endothelial nitric oxide synthase activity and serum nitric oxide levels. Decrease of serum sodium and potassium levels. Decrease of oxidative stress in serum, heart and kidney.
Decrease of renal and cardiac hypertrophy.
Ojha S. 201229 High N:40 (4 groups)
rat model of isoproterenol-induced cardiotoxicity 		Group 1- normal saline
Group 2-Hydroalcoholic extract of EO 100 mg/kg PO
Group 3- EO 250 mg/kg PO
Group 4- EO 500 mg/kg PO for 30 days with concurrent isoproterenol (85 mg/kg SC) on 29th and 30th days. 		Left ventricular pressure dynamics: peak positive pressure development, peak negative pressure decline and end diastolic pressure. Antioxidant enzymes,
superoxide dismutase, catalase and glutathione peroxidase and myocyte-injury-specific marker enzymes creatine phosphokinase-MB and lactate dehydrogenase in heart 		Restoration of hemodynamic and left ventricular function along with preservation of antioxidants, reduction of myocyte-injury-specific marker enzymes and inhibition of lipid peroxidation in EO groups.
Santoshkumar J. 201330 High N:30 (5 groups)
cholesterol-induced hypercholesterolemic rats 		Group 1- normal saline
Group 2- powdered EO 540 mg/kg/day PO with normal diet
Group 3- high fat diet
Group 4- high fat diet and EO 540 mg/kg/day
Group 5- high fat diet and atorvastatin 7.2 mg/kg/day, PO
for 8 weeks 		Serum TC,TG, LDL-C, HDL-C and
atherogenic index 		Decrease of TC, TG and LDL-C and atherogenic index and increase of HDL-C in EO and atorvastatin groups.
Rao TP. 201331 Medium Human umbilical vein endothelial cells.
N: 40 rats (2 groups) LPS-induced endotoxemia rat model 		In vitro application of EO water soluble extract (1-100 μ g/mL) on HUVEC in the presence of LPS.
Group 1- control
Group 2-
Single dose of EO water soluble extract 50 mg/kg PO 		LPS - induced tissue factor expression; von Willebrand factor level;
LPS-induced adhesion of human monocytic cells (THP-1) to
HUVEC; Expression of endothelial-leucocyte adhesion molecule-1 (E-selectin) in HUVEC.
Pro-inflammatory cytokines TNF-α and IL-6 serum levels. 		EO fruit extract reduced LPS - induced tissue factor expression and von Willebrand factor release in HUVEC
and decreased LPS-induced adhesion of human monocytic cells (THP-1) to
HUVEC and reduced expression of endothelial-leucocyte adhesion molecule-1 (E-selectin) in HUVEC.
Reduction of TNF-α and IL-6.
Thirunavukkarasu M. 201532 High N:40 (4 groups)
rat model of cardiac IRI 		Group1- control
sham
Group 2- aqueous PE extract (100 mg/kg/day PO) for 30 days
Group 3- control and IRI
Group 4- PE and IRI

 Western blot analysis and immunohistochemistry, phosphorylated Akt and GSK3-β, nitrotyrosine and caspase-3 expression, echocardiography Preservation of myocardium during IRI through upregulation of PI3K/Akt/GSK3β/β-catenin.
Increased ejection fraction and fractional shortening and decreased left ventricular internal diameter in
electrocardiography of experimental subjects compared to controls.
Open in a new tab

N: sample size, EO: Emblica officinalis or Amla or PE: Phyllanthus emblica, TC: total cholesterol, TG: triglyceride, LDL: low density lipoprotein, HDL: high density lipoprotein, VLDL: very low density lipoprotein, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, hs-CRP: high-sensitivity C reactive protein, EOT: Emblica officinalis tannoids, IRI: Ischemia-reperfusion injury, SOD: superoxide dismutase, TBARS: thiobarbituric acid reactive substances, HUVEC: human umbilical vein endothelial cells, LPS: lipopolysaccharide, HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A , PO: orally, DOCA-salt: deoxycorticosterone acetate, LDH: Lactate dehydrogenase

Table 3. Summary of the clinical pharmacological studies regarding the cardiovascular effects of Emblica officinalis .

Author, year JADAD score (out of 5) Level of evidence/study design/
participants/inclusion criteria 		Intervention/control group Outcome measure Results
Antony B. 200833 <3 Level II
quasi-experimental hypercholesterolemic (TC 190 – 310 mg/dL) patients. 		Group1- n:22, aqueous extract of EO 500 mg o.d. PO for 6 months
Group 2- n:17, aqueous extract of EO 1000 mg o.d. PO for 6 months 		Serum TC, LDL-C, VLDL-C, TG,
HDL-C and CRP 		Reduction of TC, TG, LDL-C, VLDL-C and CRP and increase in
HDL-C in both groups
Gopa B., 201234 <3 Level II
quasi-experimental
N:60, type II hypercholestrolemic patients (TC>240 mg/dL) 		Group 1- n:40,
500 mg amla capsule (dried amla fruit juice powder) o.d. PO for 42 days
Group 2- n:20, simvastatin 20 mg o.d. PO for 42 days 		Serum TC, TG, LDL-C,VLDL-C, HDL-C Both treatments reduced TC, LDL-C,VLDL-C and TG and increased HDL-C
Gopa B, 201234 <3 Level II
quasi-experimental
N:38, hypertensive patients (there is not further explanation) 		Group 1- n:28, 500 mg amla capsule o.d. PO for 42 days
Group 2- n:10, simvastatin 20 mg o.d. PO for 42 days 		Systolic and diastolic blood pressure 21 patients on amla and 6 on simvastatin therapy showed improvement in blood pressure control
Usharani P 201335 >3 Level I
RCT
N:80
type 2 diabetic patients
HbA1c 7%-9% 		Group1- PE extract 250 mg b.i.d. PO
Group 2- PE extract 500 mg b.i.d. PO
Group 3 -atorvastatin 10 mg o.d.PO + placebo
Group 4 - placebo b.i.d. PO for 12 weeks 		Change in endothelial function identified on salbutamol challenge, changes in serum malondialdehyde, nitric oxide, glutathione, hs-CRP, lipid profile and HbA1c Reduction of endothelial reflection index in PE and atorvastatin groups, showing improvement of endothelial function possibly via anti-inflammatory and antioxidant actions.
Reduction of serum total cholesterol, LDL-C, VLDL-C, TG, HbA1c, hs-CRP and MDA in PE and atorvastatin groups.
Increased serum HDL-C, NO and glutathione in PE and atorvastatin groups.
Sinha RR et al 201436 <3 Level I
Randomized open label trial,
type II hypercholestrolemic (TC>240 mg/dL and LDL-C>130 mg/dL) and hypertensive patients (there is not further explanation) 		Group1 - n:45, 500 mg amla tablet (dried EO juice) b.i.d. PO for 16 weeks
Group 2- n:48, atorvastatin 10 mg o.d. PO for 16 weeks 		Serum TC, TG, HDL-C, LDL-C and VLDL-C levels, systolic and diastolic blood pressure Amla was better in decreasing TG and increasing HDL-C,
atrovastatin was better in decreasing TC, LDL-C and VLDL-C. BP did not significantly change.
Fatima N 201437 >3 Level I
crossover RCT
N: 12 healthy participants 		Aqueous extract of PE(250 mg) b.i.d. PO for 14 days
Group 2- placebo capsule contains microcrystalline cellulose (49.7% w/w), lactose (49.5% w/w) and magnesium stearate (0.69% w/w) b.i.d. PO for 14 days 		Heart rate, augmentation pressure, augmentation index (AIx), subendocardial viability ratio (SEVR), radial and aortic blood pressure were recorded before and after cold pressor test PE extract decreased AIx, showing lowered systemic arterial stiffness. The extract reduced radial and aortic BP. It increased SEVR, showing increased myocardial oxygen supply/demand ratio.
Fatima N 201438 >3 Level I
Crossover RCT
N:10 type 2 diabetic patients 		Group1- 500 mg PE extract
Group 2- 75 mg clopidogrel
Group 3- 75 mg aspirin
Group 4-500 mg PE + 75 mg clopidogrel
Group 5- 500 mg PE + 75 mg aspirin, all as single dose.
After single dose study and washout period, patients received
Group 1-500 mg PE extract b.i.d.
Group 2- 75 mg clopidogrel o.d.
Group 3- 75 mg aspirin o.d.
Group 4-combinations for 10 days. All treatments were given PO. 		Platelet aggregation, bleeding time, clotting time Decrease of platelet aggregation and increase of bleeding and clotting time compared to baseline in all groups
Khanna S. 201539 <3 Level III
quasi-experimental
N:15
overweight/class-1 obese adults ( BMI: 25-35) 		Aqueous extract of PE(500 mg) b.i.d. PO for 12 weeks Serum hs-CRP level and platelet aggregation Decrease in hs-CRP levels and downregulation of ADP- and collagen-induced platelet aggregation
Open in a new tab

RCT: randomized controlled trial, n: sample size, b.i.d.: two times daily, PO: orally. o.d.: once daily, BMI: body mass index, EO: Emblica officinalis, PE: Phyllanthus emblica, TC: total cholesterol, TG: triglyceride, LDL: low density lipoprotein, HDL: high density lipoprotein, VLDL: very low density lipoprotein, BP: blood pressure, , hs-CRP: high-sensitivity C reactive protein, BP: blood pressure, MDA: malondialdehyde, Aix: augmentation index, SEVR: subendocardial viability ratio, CPT: cold pressure test, NO: nitric oxide, ADP: Adenosine diphosphate.

The effects given in the results sections of the tables are statistically significant, unless otherwise stated.

Discussion

This review collected and presented the evidences concerning the effects of EO on hyperlipidemia, hypertension, myocardial and endothelial function, cardiac specific antioxidants, and coagulation factors.

The results indicate that animal studies constitute the majority of EO-associated cardiovascular research. The plant affects a variety of cardiovascular parameters and has diverse cardiovascular pharmacological activities including antiatherogenic, anticoagulant, antidyslipidemic, antihypertensive, anti-inflammatory, antioxidant, antiplatelet, vasodilatory, and lipid deposition inhibitory effects. Moreover, it improves vascular endothelial function and prevents from both myocardial ischemia/reperfusion injury and doxorubicin and isoproterenol cardiotoxicity.

A few clinical studies have also been performed; nonetheless, the number of high quality clinical studies is not sufficiently large to provide a conclusive proposition on the efficacy of this plant in CVD.

The EO fruit is safe, and no side effects have been reported in clinical studies. In rats, the oral administration of the hydromethanolic (20:80) extract up to 2000 mg/kg over 15 days has not shown any clinical signs of toxicity.40 The animal studies demonstrated that the EO extract has anti-platelet activity and may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants such as warfarin or heparin, anti-platelet drugs such as clopidogrel, and non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen or naproxen. Phyllanthus emblica extract interacts pharmacodynamically with clopidogrel and ecosprin in patients with type II diabetes mellitus.38

The EO fruit extract reduces blood sugar levels.41,42 Thus, caution should be taken when using hypoglycemic medications, and patients taking insulin or drugs for diabetes need to be monitored closely. In addition, EO decreases serum lipid levels; hence, cholesterol- or triglyceride-lowering medications should be taken with caution.

EO fruit is also a rich source of tannin and may interfere with intestinal absorption of iron.43

Since EO is a rich source of ascorbic acid, it may trigger gastric hyperacidity and constipation. Alongside this, in the PM literature, it is believed that EO has a cold and dry nature and may have an astringent property. To reduce the astringent effect of EO, it is advised to use as a jam or to consume it together with almond oil and honey.12 These must be considered in patients taking medications for their cardiovascular or other organs’ disorders.

Overall, it is concluded that EO affects various cardiovascular disorders and risk factors. However, there is not sufficient clinical evidence to suggest that EO has efficacy in CVD prevention and treatment. Further studies, especially clinical trials, with EO in all fields of cardiovascular pharmacology are needed. Identification of the bioactive compounds and mechanisms mediating the cardiovascular effects of EO is also suggestable.

Competing interests

This review was not funded and there is no conflict of interest.

Ethical approval

Not applicable.

Acknowledgement

The authors thank Ms. Mahsima Abdoli for her cooperation in retrieval of the articles.

Please cite this article as: Hashem-Dabaghian F, Ziaee M, Ghaffari S, Nabati F, Kianbakht S. A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn. J Cardiovasc Thorac Res 2018;10(3):118-128. doi: 10.15171/jcvtr.2018.20.

References

  • 1.GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. doi: 10.1016/S0140-6736(16)310121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M. et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360. doi: 10.1161/CIR.0000000000000350. [DOI] [PubMed] [Google Scholar]
  • 3.Kianbakht S, Hashem Dabaghian F. Antiobesity and anorectic effects of saffron and its constituent crocin in obese Wistar rat. J Med Plant. 2015;14:25–33. [Google Scholar]
  • 4.Kianbakht S, Abasi B, Hashem Dabaghian F. Improved lipid profile in hyperlipidemic patients taking Vaccinium arctostaphylos fruit hydroalcoholic extract: a randomized double-blind placebo-controlled clinical trial. Phytother Res. 2014;28(3):432–436. doi: 10.1002/ptr.5011. [DOI] [PubMed] [Google Scholar]
  • 5.Kianbakht S, Nabatai F, Abasi B. Salvia officinalis leaf (sage) extract as add-on to statin therapy in hypercholesterolemic type 2 diabetic patients: a randomized clinical trial. Int J Mol Cell Med. 2016;5(3):141–148. [PMC free article] [PubMed] [Google Scholar]
  • 6.Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7(Suppl1):S21–S31. doi: 10.21037/cdt.2017.03.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Khan KH. Roles of Emblica officinalis in medicine - a review. Bot Res Int. 2009;2(4):218–228. [Google Scholar]
  • 8.Jain SK, Khurdiya DS. Vitami. Vitamin C enrichment of fruit juice based ready-to-serve beverages through blending of Indian gooseberry (Emblica officinalis Gaertn) juice. Plant Foods Hum Nutr. 2004;59(2):63–66. doi: 10.1007/s11130-004-0019-0. [DOI] [PubMed] [Google Scholar]
  • 9.El-Desouky SK, Ryu SY, Kim YK. A new cytotoxic acylated apigenin glucoside from Phyllanthus emblica L. Nat Prod Res. 2008;22(1):91–95. doi: 10.1080/14786410701590236. [DOI] [PubMed] [Google Scholar]
  • 10.Barthakhur NN, Arnold NP. Chemical analysis of the emblic (Phyllanthus emblica L) and its potential as a food source. Sci Hort. 1992;47(1-2):99–105. [Google Scholar]
  • 11.Rastogi S, Pandey MM, Rawat AK. Traditional herbs: a remedy for cardiovascular disorders. Phytomed. 2016;23(11):1082–1089. doi: 10.1016/j.phymed.2015.10.012. [DOI] [PubMed] [Google Scholar]
  • 12. Aghili M. Makhzan al adviye. Tehran: Sabz Avang; 2004.
  • 13.Sobhani Z, Nami SR, Emami SA, Sahebkar A, Javadi B. Medicinal plants targeting cardiovascular diseases in view of Avicenna. Curr Pharm Des. 2017;23(17):2428–2443. doi: 10.2174/1381612823666170215104101. [DOI] [PubMed] [Google Scholar]
  • 14. Ibn Sina M. Al-Qanun fi al-tib. Beirut: Al Alami Lematbutat; 2005.
  • 15.Ghorbani F, Nazem E, Imani A, Faghihi M, Keshavarz M. Cardiotonic drugs from the Avicenna’s point of view. Iran J Public Health. 2015;44(1):153–154. [PMC free article] [PubMed] [Google Scholar]
  • 16.Mirunalini S, Vaithiyanathan V, Krishnaveni M. Amla: a novel Ayurvedic herb as a functional food for health benefits – a mini review. Int J Pharm Pharm Sci. 2013;5(Suppl1):1–4. [Google Scholar]
  • 17.Dasaroju S, Gottumukkala KM. Current trends in the research of Emblica officinalis (amla): a pharmaceutical perspective. Int J Pharm Sci Rev Res. 2014;24(2):150–159. [Google Scholar]
  • 18.Jain R, Pandey R, Mahant RN, Rathore DS. A review on medicinal importance of Emblica officinalis. Int J Paharm Sci Res. 2015;6(1):72–84. doi: 10.13040/IJPSR.0975-8232. [DOI] [Google Scholar]
  • 19.Berger VW, Alperson SY. A General Framework for the Evaluation of Clinical Trial Quality. Rev recent clin trials. 2009;4(2):79–88. doi: 10.2174/157488709788186021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Pharmacol Pharmacother. 2010 Jul-Dec;1(2):94–99. doi: 10.4103/0976-500X.72351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Thakur CP, Thakur B, Singh S, Sinha PK, Sinha SK. The Ayurvedic medicines Haritaki, Amla and Bahira reduce cholesterol-induced atherosclerosis in rabbits. Int J Cardiol. 1988;21(2):167–175. doi: 10.1016/0167-5273(88)90219-7. [DOI] [PubMed] [Google Scholar]
  • 22.Mathur R, Sharma A, Dixit VP, Varma M.. Hypolipidemic effect of fruit juice of Emblica officinalis in cholesterol-fed rabbits. J Ethnopharmacol. 1996;50(2):61–68. doi: 10.1016/0378-8741(95)01308-3. [DOI] [PubMed] [Google Scholar]
  • 23.Anila L, Vijayalakshmi NR. Flavonoids from Emblica officinalis and Mangifera indica–effectiveness for dyslipidemia. J Ethnopharmacol. 2002;79(1):81–87. doi: 10.1016/s0378-8741(01)00361-0. [DOI] [PubMed] [Google Scholar]
  • 24.Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Effect of bioactive tannoid principles of Emblica officinalis on ischemia-reperfusion-induced oxidative stress in rat heart. Phytomed. 2002;9(2):171–174. doi: 10.1078/0944-7113-00090. [DOI] [PubMed] [Google Scholar]
  • 25.Rajak S, Banerjee SK, Sood S, Dinda AK, Gupta YK, Gupta SK. et al. Emblica officinalis causes myocardial adaptation and protects against oxidative stress in ischemic-reperfusion injury in rats. Phytother Res. 2004;18(1):54–60. doi: 10.1002/ptr.1367. [DOI] [PubMed] [Google Scholar]
  • 26.Antony B, Merina B, Sheeba V, Mukkadan J. Effect of standardized amla extract on atherosclerosis and dyslipidemia. Ind J Pharm Sci. 2006;68(4):437–441. [Google Scholar]
  • 27.Patel SS, Goyal RK. Prevention of diabetes-induced myocardial dysfunction in rats using the juice of the Emblica officinalis fruit. Exp Clin Cardiol. 2011;16(3):87–91. [PMC free article] [PubMed] [Google Scholar]
  • 28.Bhatia J, Tabassum F, Sharma AK, Bharti S, Golechha M, Joshi S. et al. Emblica officinalis exerts antihypertensive effect in a rat model of DOCA-salt-induced hypertension: role of (p) eNOS, NO and oxidative stress. Cardiovasc Toxicol. 2011;11(3):272–279. doi: 10.1007/s12012-011-9122-2. [DOI] [PubMed] [Google Scholar]
  • 29.Ojha S, Golechha M, Kumari S, Arya DS. Protective effect of Emblica officinalis (amla) on isoproterenol-induced cardiotoxicity in rats. Toxicol Ind Health. 2012;28(5):399–411. doi: 10.1177/0748233711413798. [DOI] [PubMed] [Google Scholar]
  • 30.Santoshkumar J, Manjunath S. Sakhare Pranavkumar M A study of anti-hyperlipidemia, hypolipidemic and anti-atherogenic activity of fruit of Emblica officinalis (amla) in high fat fed albino rats. Int J Med Res Health Sci. 2013;2(1):70–77. [Google Scholar]
  • 31.Rao TP, Okamoto T, Akita N, Hayashi T, Kato-Yasuda N, Suzuki K. Amla (Emblica officinalis Gaertn) extract inhibits lipopolysaccharide-induced procoagulant and pro-inflammatory factors in cultured vascular endothelial cells. Br J Nutr. 2013;110(12):2201–2206. doi: 10.1017/S0007114513001669. [DOI] [PubMed] [Google Scholar]
  • 32.Thirunavukkarasu M, Selvaraju V, Tapias L, Sanchez JA, Palesty JA, Maulik N. Protective effects of Phyllanthus emblica against myocardial ischemia-reperfusion injury: the role of PI3-kinase/glycogen synthase kinase 3β/β-catenin pathway. J Physiol Biochem. 2015;71:623–633. doi: 10.1007/s13105-015-0426-8. [DOI] [PubMed] [Google Scholar]
  • 33.Antony B, Benny M, Kaimal TNB. A pilot clinical study to evaluate the effect of Emblica officinalis extract (AMLAMAX TM) on markers of systemic inflammation and dyslipidemia. Indian J Clin Biochem. 2008;23(4):378–381. doi: 10.1007/s12291-008-0083-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gopa B, Bhatt J, Hemavathi KG. A comparative clinical study of hypolipidemic efficacy of amla (Emblica officinalis) with 3-hydroxy-3-methylyglutaryl-coenzyme-A reductase inhibitor simvastatin. Indian J Pharmacol. 2012;44(2):238–242. doi: 10.4103/0253-7613.93857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Usharani P, Fatima N, Muralidhar N. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes Metab Syndr Obes. 2013;6:275–284. doi: 10.2147/DMSO.S46341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sinha R. R, Sharma N, Advani U, Dadheech G, Kulshreshtha Sh, Parakh R Comparative Study of Hypolipidemic Effects of Atorvastatin With Emblica Officinalis (Amla) In Patients of Type Ii Hyperlipidemia. World J Pharm Res. 2014;3(2):2799–810. [Google Scholar]
  • 37.Fatima N, Pingali U, Pilli R. Evaluation of Phyllanthus emblica extract on cold pressor induced cardiovascular changes in healthy subjects. Pharmacognosy Res. 2014;6(1):29–35. doi: 10.4103/0974-8490.122914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Fatima N, Pingali U, Muralidhar N. Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. Phytomed. 2014;21(5):579–585. doi: 10.1016/j.phymed.2013.10.024. [DOI] [PubMed] [Google Scholar]
  • 39.Khanna S, Das A, Spieldenner J, Rink C, Roy S. Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. J Med Food. 2015;18(4):415–420. doi: 10.1089/jmf.2014.0178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Nain P, Saini V, Sharma S, Nain J. Antidiabetic and antioxidant potential of Emblica officinalis Gaertn leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol. 2012;142(1):65–71. doi: 10.1016/j.jep.2012.04.01441-. [DOI] [PubMed] [Google Scholar]
  • 41.Ansari A, Shahriar MS, Hassan MM, Das SR, Rokeya B, Haque MA. et al. Emblica officinalis improves glycemic status and oxidative stress in STZ induced type 2 diabetic model rats. Asian Pac J Trop Med. 2014;7(1):21–5. doi: 10.1016/S1995-7645(13)60185-6. [DOI] [PubMed] [Google Scholar]
  • 42.Shoaib Akhtar M, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011;62(6):609–16. doi: 10.3109/09637486.2011.560565. [DOI] [PubMed] [Google Scholar]
  • 43.Gowri BS, Platel K, Prakash J, Srinivasan K. Influence of amla fruits (Emblica officinalis) on the bioavailability of iron from staple cereals and pulses. Nutr Res. 2001;21:1483–92. doi: 10.1016/S0271-5317(01)00362-1. [DOI] [Google Scholar]

Articles from Journal of Cardiovascular and Thoracic Research are provided here courtesy of Tabriz University of Medical Sciences

RESOURCES